Updated: FDA pulls paid Eisai consultant from temporary role on adcomm reviewing Eisai's new Alzheimer's drug
The FDA’s advisory committees of outside experts are supposed to offer the agency with unbiased reviews of the sponsor’s efficacy and safety data before them …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
